ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development

Current Pharmaceutical Design

Volumn 20, Issue 5, 2014, Pages 793-807

  Choi, Young Hee ^a,b   Yu, Ai Ming ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Dongguk University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABC transporter; Cancer therapy; Drug development; Multidrug resistance; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE;

ATPASE ACTIVITY ASSAY; CANCER CHEMOTHERAPY; DRUG DEVELOPMENT; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; ORGAN PERFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; TISSUE PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE TRANSPORT MODULATORS; MODELS, BIOLOGICAL; MOLECULAR CONFORMATION; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84895114924     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282005140214165212     Document Type: Review

References (217)

1. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749-57.
2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-83.
3. Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Current drug delivery 2007; 4: 324-33.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
5. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14 Suppl 1: 35-48.
6. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays in biochemistry 2011; 50: 209-32.
7. Rochat B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr Cancer Drug Targets 2009; 9: 652-74.
8. Tegos GP, Haynes M, Strouse JJ, et al. Microbial efflux pump inhibition: tactics and strategies. Current pharmaceutical design 2011; 17: 1291-302.
9. Sa JM, Chong JL, Wellems TE. Malaria drug resistance: new observations and developments. Essays in biochemistry 2011; 51: 137-60.
10. Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS letters 2011; 585: 1551-62.
11. Nikaido H. Multidrug resistance in bacteria. Annual review of biochemistry 2009; 78: 119-46.
12. O'Callaghan T. Introduction: The prevention agenda. Nature 2011; 471: S2-4.
13. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
14. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995; 20: 435-9.
15. Espinosa E, Zamora P, Feliu J, Gonzalez Baron M. Classification of anticancer drugs--a new system based on therapeutic targets. Cancer treatment reviews 2003; 29: 515-23.
16. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investigational new drugs 2000; 18: 299-313.
17. Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 2007; 13: 8507-15.
18. Allegra CJ, Grem JL, Yeh GC, Chabner BA. Antimetabolites. Cancer chemotherapy and biological response modifiers 1988; 10: 1-22.
19. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investigational new drugs 2006; 24: 37-77.
20. Snyder RD, Arnone MR. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutation research 2002; 503: 21-35.
21. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49: 11-9.
22. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature reviews. Cancer 2004; 4: 253-65.
23. Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nature reviews. Urology 2011; 8: 29-41.
24. Dunn BK, Ford LG. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. European J cancer prevention: the official J Eur Cancer Prevention Organisation 2007; 16: 232-42.
25. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V. Endocrine therapy of breast cancer. Current medicinal chemistry 2011; 18: 513-22.
26. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 1996; 2: 561-6.
27. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53.
28. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800-5.
29. Chahrour O, Cairns D, Omran Z. Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev Med Chem 2012.
30. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nature reviews. Drug Discov 2003; 2: 296-313.
31. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
32. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007; 10: 59-67.
33. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
34. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Eng J Med 2001; 344: 1038-42.
35. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-37.
36. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. New Eng J Med 2003; 348: 994-1004.
37. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Eng J Med 2005; 352: 786-92.
38. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS medicine 2005; 2: e73.
39. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
40. Kitazaki T, Oka M, Nakamura Y, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of Pglycoprotein in multidrug resistant cancer cells. Lung Cancer 2005; 49: 337-43.
41. Morita H, Koyama K, Sugimoto Y, Kobayashi J. Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata. Bioorganic Med Chem letters 2005; 15: 1051-4.
42. Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67: 11012-20.
43. Tiwari AK, Sodani K, Wang SR, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacol 2009; 78: 153-61.
44. K S, K TA, S S, A P, J XZ, J CJ, L SY, T TT, Chen ZS. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2 and ABCB1-mediated drug resistance Biochem Pharmacol 2012: (in press).
45. Fan D, Poste G, Seid C, et al. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Invest New Drugs 1994; 12: 185-95.
46. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47: 3039-51.
47. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 2641-58.
48. Demant EJ, Sehested M, Jensen PB. A model for computer simulation of P-glycoprotein and transmembrane delta pHmediated anthracycline transport in multidrug-resistant tumor cells. Biochim Biophys Acta 1990; 1055: 117-25.
49. Kuzmich S, Tew KD. Detoxification mechanisms and tumor cell resistance to anticancer drugs. Med Res Rev 1991; 11: 185-217.
50. Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1993; 1175: 147-54.
51. Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988; 48: 3622-5.
52. Hurley LH. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2002; 2: 188-200.
53. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 2005; 8: 311-21.
54. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Annals of oncology: official J the European Society for Medical Oncology/ESMO 2003; 14: 428-32.
55. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005; 102: 3395-400.
56. Biedler JL, Spengler BA. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture. J Natl Cancer Inst 1976; 57: 683-95.
57. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087-92.
58. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer research 2005; 65: 3509-12.
59. Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-29.
60. van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1998; 1365: 31-6.
61. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annual review of biochemistry 2002; 71: 537-92.
62. Roninson IB, Abelson HT, Housman DE, Howell N, Varshavsky A. Amplification of specific DNA sequences correlates with multidrug resistance in Chinese hamster cells. Nature 1984; 309: 626-8.
63. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-11.
64. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature reviews. Cancer 2005; 5: 275-84.
65. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
66. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
67. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
68. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-66.
69. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003; 278: 8294-9.
70. Kage K, Tsukahara S, Sugiyama T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. International J cancer. J Int Cancer 2002; 97: 626-30.
71. Loo TW, Clarke DM. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J Biological Chem 2000; 275: 5253-6.
72. Pinkett HW, Lee AT, Lum P, Locher KP, Rees DC. An inwardfacing conformation of a putative metal-chelate-type ABC transporter. Science 2007; 315: 373-7.
73. Bolhuis H, van Veen HW, Molenaar D, Poolman B, Driessen AJ, Konings WN. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO J 1996; 15: 4239-45.
74. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et biophysica acta 1976; 455: 152-62.
75. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (Pglycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
76. McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988; 48: 3959-63.
77. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
78. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-70.
79. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-9.
80. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8-13.
81. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-36.
82. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-22.
83. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
84. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27.
85. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231-59.
86. Wolf DC, Horwitz SB. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 1992; 52: 141-6.
87. Liu Y, Huang L, Hoffman T, Gosland M, Vore M. MDR1 substrates/modulators protect against beta-estradiol-17beta-Dglucuronide cholestasis in rat liver. Cancer Res 1996; 56: 4992-7.
88. King M, Su W, Chang A, Zuckerman A, Pasternak GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nature Neurosci 2001; 4: 268-74.
89. Westlake CJ, Cole SP, Deeley RG. Role of the NH2-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking. Mol Biol cell 2005; 16: 2483-92.
90. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS letters 2006; 580: 2903-9.
91. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-10.
92. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 2007; 453: 621-41.
93. Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005; 37: 720-5.
94. Ozvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001; 285: 111-7.
95. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J the National Cancer Institute 1997; 89: 917-31.
96. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clinical cancer research: an official J Am Assoc Cancer Res 1999; 5: 3352-6.
97. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 324-32.
98. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086-99.
99. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol: official J Am Soc Clin Oncol 2006; 24: 1546-53.
100. Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198: 213-9.
101. Suvannasankha A, Minderman H, O'Loughlin KL, et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004; 127: 392-8.
102. Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clinical cancer research: an official J Am Association for Cancer Res 2004; 10: 1691-7.
103. Damiani D, Tiribelli M, Calistri E, et al. The prognostic value of Pglycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006; 91: 825-8.
104. Daenen S, van der Holt B, Verhoef GE, et al. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. Leuk Res 2004; 28: 1057-67.
105. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-20.
106. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004; 22: 4290-301.
107. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Therapeut 1999; 66: 391-400.
108. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224-32.
109. Lhomme C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol: official J Am Soc Clin Oncol 2008; 26: 2674-82.
110. Kolitz JE, George SL, Marcucci G, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010; 116: 1413-21.
111. Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res: an official J Am Assoc Cancer Res 2002; 8: 383-93.
112. Minderman H, O'Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 2004; 10: 1826-34.
113. Rago RP, Einstein A, Jr., Lush R, et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherap Pharmacol 2003; 51: 297-305.
114. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 2002; 27: 119-26.
115. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000; 6: 4186-91.
116. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010; 116: 4077-85.
117. Kelly RJ, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical cancer research: an official J Am Assoc Cancer Res 2011; 17: 569-80.
118. Pang Z, Feng L, Hua R, et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Molecular pharmaceutics 2010; 7: 1995-2005.
119. Yu AM. Small interfering RNA in drug metabolism and transport. Current drug metabolism 2007; 8: 700-8.
120. Yu AM. Role of microRNAs in the regulation of drug metabolism and disposition. Expert opinion on drug metabolism & toxicology 2009; 5: 1513-28.
121. Yu AM, Pan YZ. Noncoding microRNAs: Small RNAs play a big role in regulation of ADME? Acta Pharmaceutica Sinica B 2012; 2: 91-9.
122. Lu C, Liao M, Cohen L, Xia CQ. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Current drug discovery technologies 2010; 7: 199-222.
123. Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clinical pharmacology and therapeutics 2009; 85: 173-81.
124. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal Pglycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53.
125. Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of Pglycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clinical pharmacology and therapeutics 2000; 68: 345-55.
126. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548-9.
127. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Therapeut 2005; 77: 503-14.
128. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995; 31A: 1295-8.
129. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol: official J Am Soc Clin Oncol 2002; 20: 2943-50.
130. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; Int J Clin Chem 2006; 373: 99-103.
131. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Therapeut 2009; 86: 197-203.
132. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006; 98: 1739-42.
133. Cha PC, Mushiroda T, Zembutsu H, et al. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Human Genet 2009; 54: 572-80.
134. Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007; 8: 341-63.
135. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biological Chem 1989; 264: 11693-8.
136. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biological Chem 1992; 267: 24995-5002.
137. Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992; 102: 879-85.
138. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-7.
139. Lew VL, Hockaday A, Freeman CJ, Bookchin RM. Mechanism of spontaneous inside-out vesiculation of red cell membranes. J Cell Biol 1988; 106: 1893-901.
140. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988; 85: 3580-4.
141. Karlsson JE, Heddle C, Rozkov A, et al. High-activity pglycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug metabolism and disposition: the Biological Fate Chemicals 2010; 38: 705-14.
142. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003; 63: 1094-103.
143. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267: 4854-8.
144. Wu CP, Woodcock H, Hladky SB, Barrand MA. cGMP (guanosine 3',5'-cyclic monophosphate) transport across human erythrocyte membranes. Biochemical Pharmacol 2005; 69: 1257-62.
145. Miliotis T, Ali L, Palm JE, et al. Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function. Drug metabolism and disposition: the Biological Fate Chemicals 2011; 39: 2440-9.
146. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoproteinmediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem/FEBS 1999; 259: 841-50.
147. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem/FEBS 1997; 250: 115-21.
148. Ninomiya M, Ito K, Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug metabolism and disposition: Biological Fate Chemicals 2005; 33: 225-32.
149. Ishizuka H, Konno K, Shiina T, et al. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Therapeut 1999; 290: 1324-30.
150. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005; 68: 800-7.
151. Center MS, Zhu Q, Sun H. Mutagenesis of the putative nucleotidebinding domains of the multidrug resistance associated protein (MRP). Analysis of the effect of these mutations on MRP mediated drug resistance and transport. Cytotechnology 1998; 27: 61-69.
152. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63: 5538-43.
153. Rosenberg MF, Velarde G, Ford RC, et al. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 2001; 20: 5615-25.
154. Mao Q, Leslie EM, Deeley RG, Cole SP. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochimica et Biophysica acta 1999; 1461: 69-82.
155. Glavinas H, Kis E, Pal A, et al. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug metabolism and disposition: Biological Fate Chemicals 2007; 35: 1533-42.
156. Hassan HE, Myers AL, Lee IJ, Chen H, Coop A, Eddington ND. Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis. Drug metabolism and disposition: Biological Fate Chemicals 2010; 38: 157-67.
157. Abraham I, Jain S, Wu CP, et al. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochem Pharmacol 2010; 80: 1497-506.
158. al-Shawi MK, Senior AE. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biological Chem 1993; 268: 4197-206.
159. Hamada H, Tsuruo T. Purification of the 170-to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170-to 180-kilodalton membrane glycoprotein is an ATPase. J Biological Chem 1988; 263: 1454-8.
160. Urbatsch IL, Sankaran B, Weber J, Senior AE. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biological Chem 1995; 270: 19383-90.
161. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Therapeut 2001; 299: 164-70.
162. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug metabolism and disposition: Biological Fate Chemicals 2005; 33: 637-43.
163. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 2006; 3: 87-93.
164. Xie J, Lei C, Hu Y, Gay GK, Bin Jamali NH, Wang CH. Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer. Curr Pharm Des 2010; 16: 2331-40.
165. Gaillard PJ, van der Sandt IC, Voorwinden LH, et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res 2000; 17: 1198-205.
166. Wang EJ, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of Pglycoprotein. Drug metabolism and disposition: Biological Fate Chemicals 2000; 28: 522-8.
167. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and-520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011; 81: 783-92.
168. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75: 1374-9.
169. Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV. Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug metabolism and disposition: Biological Fate Chemicals 2012; 40: 304-12.
170. Artursson P, Ungell AL, Lofroth JE. Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 1993; 10: 1123-9.
171. Wei Y, Neves LA, Franklin T, Klyuchnikova N, Placzek B, Hughes HM, Curtis CG. Vascular perfused segments of human intestine as a tool for drug absorption. Drug metabolism and disposition: Biological Fate Chemicals 2009; 37: 731-6.
172. Booth CL, Brouwer KR, Brouwer KL. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 1998; 58: 3641-8.
173. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Therapeut 1993; 266: 1620-5.
174. Emi Y, Tsunashima D, Ogawara K, Higaki K, Kimura T. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 1998; 87: 295-9.
175. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug metabolism and disposition: Biological Fate Chemicals 1996; 24: 142-7.
176. Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 2005; 67: 923-8.
177. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 1998; 87: 73-5.
178. Adachi Y, Suzuki H, Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res 2003; 20: 1163-9.
179. Watanabe T, Miyauchi S, Sawada Y, et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 1992; 16: 77-88.
180. Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 2005; 33: 1-9.
181. Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Therapeut 2006; 316: 762-71.
182. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Therapeut 1993; 266: 1614-9.
183. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. A J Physiol 1984; 247: H484-93.
184. Smith QR, Takasato Y. Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann New York Acad Sci 1986; 481: 186-201.
185. Cisternino S, Rousselle C, Dagenais C, Scherrmann JM. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res 2001; 18: 183-90.
186. Zhao R, Pollack GM. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain. Biochemical Pharmacol 2009; 78: 1052-9.
187. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of Pglycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem 1996; 67: 1688-93.
188. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 1997; 49: 80-8.
189. Chikhale EG, Burton PS, Borchardt RT. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. The J Pharmacol Exp Therapeut 1995; 273: 298-303.
190. Lemaire M, Bruelisauer A, Guntz P, Sato H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistancereversing cyclosporin, in rats. Cancer Chemotherap Pharmacol 1996; 38: 481-6.
191. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J cerebral blood flow and metabolism: official J Int Soc Cerebral Blood Flow Metabol 2000; 20: 381-6.
192. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem/FEBS 1999; 259: 18-24.
193. Jiang XL, Gonzalez FJ, Yu AM. Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metabol Rev 2011; 43: 27-40.
194. Schellens JH, Malingre MM, Kruijtzer CM, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci: official J Eur Fed Pharm Sci 2000; 12: 103-10.
195. van Waterschoot RA, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 2011; 63: 390-410.
196. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
197. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drugtransporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028-33.
198. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin investigation 1996; 97: 2517-24.
199. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin investigation 1995; 96: 1698-705.
200. Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Med 1997; 3: 1275-9.
201. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 1997; 57: 5238-42.
202. Wijnholds J, deLange EC, Scheffer GL, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Investigation 2000; 105: 279-85.
203. Sugiyama D, Kusuhara H, Lee YJ, Sugiyama Y. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res 2003; 20: 1394-400.
204. Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro-Oncol 2010; 12: 1043-9.
205. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002; 99: 15649-54.
206. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002; 99: 12339-44.
207. van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5 b]pyridine. Cancer Res 2003; 63: 6447-52.
208. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65: 2577-82.
209. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nature Med 2005; 11: 127-9.
210. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005; 67: 1758-64.
211. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug metabolism and disposition: Biological Fate Chemicals 2006; 34: 690-5.
212. Salphati L, Lee LB, Pang J, Plise EG, Zhang X. Role of Pglycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug metabolism and disposition: Biological Fate Chemicals 2010; 38: 1422-6.
213. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug metabolism and disposition: Biological Fate Chemicals 2009; 37: 439-42.
214. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 2008; 73: 949-59.
215. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 2007; 102: 1749-57.
216. Schuetz EG, Umbenhauer DR, Yasuda K, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000; 57: 188-97.
217. Shen HW, Jiang XL, Gonzalez FJ, Yu AM. Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metabol 2011; 12: 997-1006.